Form 4: Tango Therapeutics Director John Ketchum Equity Grant

Director John Ketchum received an equity grant of 4,000 restricted stock units and 25,000 stock options from Tango Therapeutics.

Summary

• Director John B. Ketchum was granted 4,000 restricted stock units (RSUs) on June 5, 2026.
• The RSUs vest on the earlier of June 5, 2027, or the date of the next annual stockholders meeting.
• Director Ketchum was also granted 25,000 stock options with an exercise price of $20.22.
• The stock options vest in 12 equal monthly installments starting July 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedules for both RSUs and options encourage director retention.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Market volatility affecting the value of the granted equity.
• Dependence on continuous service for the vesting of the granted securities.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is standard practice in the biotechnology sector to align leadership with long-term R&D and clinical trial milestones.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with compensation structures at mid-cap biotech firms.
• The one-year vesting period for options is relatively aggressive compared to the multi-year vesting often seen in larger pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of stock options beginning July 5, 2026.
• Vesting of RSUs on June 5, 2027, or the next annual meeting.

Key Dates

Keywords

Tango Therapeutics, TNGX, Form 4, Director Compensation, Equity Grant, Insider Transaction